Please provide your email address to receive an email when new articles are posted on . Althera announced the FDA approved its rosuvastatin/ezetimibe tablets as an adjunct to diet for treatment of ...

Dallas, Texas— The US Food and Drug Administration (FDA) has approved a new lipid-lowering combination tablet that includes atorvastatin, which went off patent in 2011, and ezetimibe (Zetia, ...

- NEXLIZET Lowered LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins -- First Non-Statin, LDL-Cholesterol Lowering Combination Medicine Ever Approved -- Esperion’s ...

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe GMbH (hereafter, ‘Daiichi Sankyo’) today announced positive initial results from the 12-week Phase 2 bempedoic acid / ezetimibe fixed dose combination ...

-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at ...

For patients with homozygous familial hypercholesterolemia (HoFH) taking lomitapide, the dose should not exceed 10/20 mg/day (or 10/40 mg/day for patients who have previously taken simvastatin 80 ...

WHITEHOUSE STATION, New Jersey — Merck has resubmitted a new drug application (NDA) for the combination atorvastatin and ezetimibe (Zetia) tablet to the US Food and Drug Administration (FDA). Back in ...

Reduce elevated total-C and LDL-C in patients with homozygous familial; hypercholesterolemia (HoFH), in combination with atorvastatin or simvastatin; and Reduce elevated sitosterol and campesterol in ...

Please provide your email address to receive an email when new articles are posted on . Long-term cholesterol-lowering treatment with ezetimibe plus simvastatin reduced the risk for MI, stroke and ...

Merck and Schering-Plough Resolve Previously Disclosed Investigation Under State Consumer Protection Statutes Related to VYTORIN® (ezetimibe/simvastatin) and ZETIA® (ezetimibe) WHITEHOUSE STATION, N.J ...